Redefining diagnosis-related groups (DRGs) for palliative care - a cross-sectional study in two German centres by Vogl, Matthias et al.
Vogl et al. BMC Palliative Care  (2018) 17:58 
https://doi.org/10.1186/s12904-018-0307-3RESEARCH ARTICLE Open AccessRedefining diagnosis-related groups (DRGs)
for palliative care – a cross-sectional study
in two German centres
Matthias Vogl1,2†, Eva Schildmann3*† , Reiner Leidl1,2, Farina Hodiamont3, Helen Kalies3, Bernd Oliver Maier4,
Marcus Schlemmer5, Susanne Roller5 and Claudia Bausewein3Abstract
Background: Hospital costs and cost drivers in palliative care are poorly analysed. It remains unknown whether
current German Diagnosis-Related Groups, mainly relying on main diagnosis or procedure, reproduce costs
adequately. The aim of this study was therefore to analyse costs and reimbursement for inpatient palliative care
and to identify relevant cost drivers.
Methods: Two-center, standardised micro-costing approach with patient-level cost calculations and analysis of the
reimbursement situation for patients receiving palliative care at two German hospitals (7/2012–12/2013). Data were
analysed for the total group receiving hospital care covering, but not exclusively, palliative care (group A) and the
subgroup receiving palliative care only (group B). Patient and care characteristics predictive of inpatient costs of
palliative care were derived by generalised linear models and investigated by classification and regression tree
analysis.
Results: Between 7/2012 and 12/2013, 2151 patients received care in the two hospitals including, but not
exclusively, on the PCUs (group A). In 2013, 784 patients received care on the two PCUs only (group B). Mean total
costs per case were € 7392 (SD 7897) (group A) and € 5763 (SD 3664) (group B), mean total reimbursement per
case € 5155 (SD 6347) (group A) and € 4278 (SD 2194) (group B). For group A/B on the ward, 58%/67% of the
overall costs and 48%/53%, 65%/82% and 64%/72% of costs for nursing, physicians and infrastructure were
reimbursed, respectively. Main diagnosis did not significantly influence costs. However, duration of palliative care
and total length of stay were (related to the cost calculation method) identified as significant cost drivers.
Conclusions: Related to the cost calculation method, total length of stay and duration of palliative care were
identified as significant cost drivers. In contrast, main diagnosis did not reflect costs. In addition, results show that
reimbursement within the German Diagnosis-Related Groups system does not reproduce the costs adequately, but
causes a financing gap for inpatient palliative care.
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Patients in palliative care (PC) usually suffer from cancer
or advanced neurological, cardiac, pulmonary or renal dis-
ease, with a highly individual care utilization [1]. Needs of
patients and their family members are diverse. They in-
clude relief of symptoms, psychosocial and spiritual as
well as practical support [2, 3] – care taking dimensions
which need to be reflected by reimbursement calculation.
After its introduction in 2003, it has continuously been
discussed whether the German Diagnosis-Related Groups
(G-DRG) system is an appropriate payment scheme for
hospital palliative care units (PCUs) [4, 5]. PC focuses on
specific patient and family needs regardless of the under-
lying diagnosis. In contrast, patient classification by the
DRG system mainly relies on main diagnosis or
procedures.
In Australia, where the G-DRG system is derived from,
[6] “acute care” (treatment driven primarily by patient’s
diagnosis) is distinguished from “subacute care” (treat-
ment driven primarily by patient’s functional status and
quality of life) [7–9]. It is acknowledged that “sub-acute
care” episodes - including PC - are not adequately classi-
fied by DRGs and require a different classification ap-
proach [10, 11]. A large Australian study demonstrated
that the complexity of the patients’ situation, reflected
by factors such as phase of illness (stable, unstable, de-
teriorating, terminal), functional status, severity of symp-
toms and age, best predicts the resource use and cost in
PC, together with the model of PC in the ambulatory
setting (multidisciplinary or nursing or medical therapy
only) [1, 9]. Consequently, Australia has implemented a
special PC reimbursement system outside the DRG-
system, based on these factors [7].
Hospital treatment costs and related cost drivers in PC
are poorly analysed [12]. It remains unknown whether
current G-DRGs, merely accounting for main diagnosis or
procedure and developed for acute inpatient care epi-
sodes, reproduce costs in PC in Germany adequately. Spe-
cifically, it is unknown to which extent, in which direction
and in which categories PC costs deviate from the DRG
reimbursement.
The aim of this study therefore was to analyse in-
patient PC costs and reimbursement, and to identify pa-
tient and care characteristics predictive of case costs.
Methods
Study design, setting and costing
PC costs were analysed in a cross-sectional, two-center
approach. Data were acquired from two German hospi-
tals for all patients who received care on their PCUs
from July 2012 to December 2013 (“group A”): a univer-
sity hospital providing 10 PCU beds, and a non-
university hospital providing PCU 30 beds. Data for
group A, including length of stay (LOS) data, refer tothe complete stay of the patients in the hospital, not
only encompassing the stay on the PCU, but also pos-
sible days on a normal ward or the intensive care unit. A
subgroup of cases with a PCU stay only in 2013 (group
B) was also analysed. For 2012, data were unavailable to
identify this subgroup.
Clinical and socio-demographic data were acquired
from hospital medical records, inpatient costs on patient
level from the hospitals’ costing systems. Costs had been
calculated using the InEK costing scheme (Institute for
the Hospital Remuneration System) [13, 14]. Investment
costs for PC were not calculated [15]. The InEK costing
scheme is an activity-based full cost approach which has
become a generally accepted national costing standard
[13]. Each cost center and cost category in a hospital is
represented in a cost-matrix, where a cost classifier is de-
fined for each cost module (combination of cost center
and cost category). For example, costs of physicians (cost
category) on the PCU are allocated to patients based on
their LOS (cost classifier). PC is part of the normal ward
cost center within this calculation, and is not specifically
reflected by any subgrouping. For most cost categories on
the ward, LOS is used as the cost classifier to allocate
costs to patients. For diagnostic or procedural cost centers
such as operating room, radiology or laboratory tests,
point systems, actual duration or surgery time are used as
cost classifiers. This kind of activity-based micro costing is
used in several countries alike and allows comparison of
costs between health care systems [16–18].
In the G-DRG-system, a procedure code for specialist
palliative care (SPC) was introduced, defined by criteria
for SPC acknowledgement and the duration of SPC
provision (< 7 days, 7–13 days, 14 to 20 days or >
20 days). A supplementary fee is provided for SPC >
7 days, increasing with the duration of SPC. We used
the actual reimbursement of each case, including supple-
mentary fees (e.g. for duration of SPC and for time-
consuming nursing care), and distributed it based on the
national average cost matrix for the respective DRG, to
analyse differences between costs and reimbursement
(profit) at the cost-module level of the cost-matrix. We
set profit distribution in relation to LOS.
Statistical analysis
Cost and reimbursement data are given as mean and
standard deviation (SD). Spearman’s rank correlation
was used to test the relationship of current cost classi-
fiers and costs. The relationship of LOS and costs is vi-
sualized by a scatterplot with a linear and LOESS fit line
(locally weighted scatterplot smoothing). LOESS was
chosen to give an intuitive, optical view on trends in the
scatterplot. Therefore, the best fitting models on local-
ized subsets of points in the plot are used instead of a
global function, to generate an overall fit line [19].
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and socio-demographic factors, on case costs, we used a
generalized linear model (GLM) with gamma distribution
and log link function. A simple ordinary least squares
(OLS) model would have required Gaussian distribution,
and was thus not able to process the right skewed (Kolmo-
gorov-Smirnov-Test, p < 0.000) case cost data (Fig. 1) [20].
The GLM suits best for the integration of high cost cases
to a single model and can reduce heteroscedasticity of
OLS residuals [21, 22]. The GLM model provides relative
cost differences for each key cost driver via exponentiated
coefficients. For the nearly normal distributed case costs
per day, we used OLS regression. Covariates included in
regression analyses (independent of being significant in bi-
variate analysis) were location, age, gender, discharge rea-
son, kind of supplementary fees for SPC, other
supplementary fees (e.g. for very costly drugs), LOS, Major
diagnostic category (MDC), number of side diagnoses and
number of operation and procedure codes. Main diagnosis
and DRG were not considered in regression analysis due
to too many values (degrees of freedom) to be reported.Fig. 1 Cost distribution per case (a) and per day (b) for group A
(total group, n = 2151)To test in multivariate analyses whether the current DRG
differentiation by main diagnosis is discriminative for
costs, MDC was used as a proxy for main diagnosis and
DRG. A p-value of < 0.05 was considered significant. Stat-
istical analyses were performed with SPSS 22.
To test a DRG-grouping based on current cost classi-
fiers and determine cut-off values, we used classification
and regression tree (CART) analysis. CART is a decision
tool that has been used in defining the Australian case-
mix classification for PC [9] and is able to maximise
homogeneity within DRGs by defining cut-off values for
the strongest predictors of costs, which serve as the
splitting variables [23].
The study was approved by the ethics committee of
Ludwig-Maximilians-Universität Munich (reference num-
ber: 24–15).
Results
Sample characteristics
Between July 2012 and December 2013, 2151 patients re-
ceived care in the two hospitals including, but not exclu-
sively, on the PCUs (group A). In 2013, 784 patients
received care on the two PCUs only (group B). Both
groups were similar regarding age, gender, and propor-
tions of malignant disease. Proportions of patients who
died on the unit, of patients who received SPC for at least
7 days and the mean number of secondary diagnoses were
also similar between groups. Mean LOS was 12 ± 10 days
for group A and 10 ± 6 days for group B (Table 1).
Costs and reimbursement
For group A, mean total costs per case were €7392 (SD
7897, range 134–132769). Mean total reimbursement per
case, including supplementary fees, was €5155 (SD 6347),
creating a total financing gap of €2237 per case. Mean case
costs per day were €578 (SD 143). 84% of the costs per case
occurred on the ward, 10% were related to diagnostics and
therapy and 4% to intensive care. However, only 70% of re-
imbursement was distributed to the cost centre “ward” (i.e.
all wards, including the PCU). 62% of the overall financing
gap was related to nursing, 15% to physicians, and 35% to
medical and non-medical infrastructure on the cost centre
“ward”, respectively. For laboratory tests, reimbursement
was more than double the costs (270%). The financing gap
on the cost centre “ward” (all wards including the PCU) was
€2599. For this cost centre, 58% of the overall costs, and
48%, 65% and 64% of costs for nursing, physicians and
(medical and non-medical) infrastructure were reimbursed,
respectively (Table 2). For group B, i.e. the subgroup of pa-
tients with a stay on a PCU only, mean total costs per case
were €5763 (SD 3664), mean total reimbursement per case
€4278 (SD 2194), creating a total financing gap of €1485.
On the PCU, the financing gap was €1767. 67% of overall
costs, and 53%, 82%, 72% of costs for nursing, physicians
Table 1 Sample characteristics
Group A = total group B = “pall. Care only” group
Number of patients n = 2151 n = 784
Variable n; mean %; SD n; mean %; SD
Location BBM 1555 72.3% 659 84.1%
LMU 596 27.7% 125 15.9%
Year 2012 1070 49.7%
2013 1081 50.3% 784 100%
Gender male 1031 47.9% 350 44.6%
female 1120 52.1% 434 55.9%
MDC respiratory system 331 15.4% 99 12.6%
hepatobiliary system and pancreas 309 14.4% 123 15.7%
digestive system 296 13.8% 127 12.2%
nervous system 288 13.4% 91 11.6%
other 262 12.2% 116 14.8%
skin, subcutaneous tissue & breast 191 8.9% 60 7.7%
kidney and urinary tract 126 5.9% 42 5.4%
female reproductive system 120 5.6% 35 4.5%
poorly differentiated neoplasms 119 5.5% 43 5.5%
male reproductive system 109 5.1% 48 6.1%
Discharge death 1299 60.4% 455 58%
home 590 27.4% 237 30.2%
hospice 159 7.4% 55 7.0%
nursing home 55 2.6% 25 3.2%
other hospital 30 1.4% 6 0.8%
other 18 0.8% 6 0.8%
Cancer yes 1497 69.6% 549 70%
no 654 30.4% 235 30%
Kind of suppl. Fee for SPC palliative care ≤6 days (=no fee) 732 34.0% 240 30.6%
palliative care 7–13 days 797 37.1% 313 39.9%
palliative care 14–20 days 466 21.7% 181 23.1%
palliative care ≥21 days 156 7.3% 50 6.4%
age (years) 69.8 12.37 70.7 11.8
length of stay (days) 12.2 10.10 9.8 6.3
number of secondary
diagnoses
14.3 6.50 14.3 5.8
number of operation/
procedure codes
4.7 5.28 3.3 1.7
BBM (Hospital Barmherzige Brüder München), LMU (University Hospital Munich), MDC (main Diagnostic Category)
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were reimbursed, respectively (Table 3). For laboratory tests,
more than 7-fold (730%) of the costs were reimbursed.
Including both standard G-DRG reimbursement and sup-
plementary fees, the benefit distribution of cases with highest
profit to highest loss shows that about 21% of all cases gener-
ated a profit of on average €1078, while 79% of all cases gen-
erated a loss of on average €3086 Euros (Fig. 2a). The benefit
distribution according to total LOS shows that for theaverage case, the break-even point was around 6–9 days,
while longer stays caused losses in most cases (Fig. 2b).
Bi- and multivariate analysis
Spearman’s correlation with costs identified total LOS,
the kind of supplementary fee for SPC (generally reflecting
duration of SPC) and the number of operation and pro-
cedure codes (German classification used to encode surgi-
cal and medical procedures) as the most relevant factors
Table 2 Mean costs and reimbursement per case in Euros, separated by cost categories and cost centers for group A (total group,
n = 2151)
Physicians Nursing Medical/
technical staff
Drugs Implants/
grafts
Material bMedical
infrastructure
bNon-medical
infrastructure
Sum %
Cost matrix of palliative care cases
Ward (including
palliative care ward)
982 2658 45 208 0 140 500 1659 6193 83.8%
Intensive care 47 114 1 46 0 27 22 55 312 4.2%
Dialysis 2 7 0 0 0 7 1 2 18 0.2%
Operating room 21 0 23 2 18 22 11 15 112 1.5%
Anesthesia 21 0 14 2 0 5 3 6 51 0.7%
Cardiac diagnostics/
therapy
1 0 0 0 1 2 0 0 5 0.1%
Endoscopic diagnostics/
therapy
6 0 7 1 2 11 5 5 36 0.5%
Radiology 29 0 36 0 3 21 16 19 125 1.7%
Laboratory tests 4 0 22 47 0 48 4 7 133 1.8%
Further diagnostics/
therapy
87 0 170 5 0 16 42 86 406 5.5%
sum 1200 2778 318 313 25 299 604 1855 7392
% 16.2% 37.6% 4.3% 4.2% 0.3% 4.0% 8.2% 25.1%
Matrix used for reimbursementa
Ward (including
palliative care ward)
638 1276 26 160 0 121 337 1035 3594 69.7%
Intensive care 55 116 2 21 0 23 19 49 286 5.5%
Dialysis 4 11 0 1 0 11 1 3 31 0.6%
Operating room 34 0 27 2 20 28 14 21 146 2.8%
Anesthesia 23 0 14 2 0 5 3 6 53 1.0%
Cardiac diagnostics/
therapy
0 0 0 0 1 1 0 0 3 0.1%
Endoscopic diagnostics/
therapy
6 0 7 0 0 6 3 5 27 0.5%
Radiology 55 0 65 1 0 19 30 47 218 4.2%
Laboratory tests 32 0 124 18 0 109 18 59 359 7.0%
Further diagnostics/
therapy
99 0 183 3 0 20 27 105 437 8.5%
sum 945 1403 450 208 22 343 453 1331 5155
% 18.3% 27.2% 8.7% 4.0% 0.4% 6.7% 8.8% 25.8%
aoverall absolute value represents actual reimbursement, distribution of absolute value represents hypothetical InEK calculation based on study patients
bmedical infrastructure: e.g. pharmacy, hygiene; non-medical infrastructure: e.g. management, energy, laundry
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main diagnosis, DRGs, and MDCs were also signifi-
cantly associated with costs, but did not correlate
highly (see Additional file 1). LOESS fit line analysis
confirms total LOS as a good cost driver in the current
costing scheme (Fig. 3).
Multivariate analysis showed that total LOS, the kind
of supplementary fee for SPC (reflecting the duration of
SPC), number of side diagnoses and location influenced
costs per case for the total group of patients (group A)
and for the patients with purely SPC (group B) (Table 4).Each additional day increased case costs by 5.6% (group
A) and 11.3% (group B), and each additional side diagnosis
increased costs by 1.5% (group A) and 1.1% (group B).
Compared to the shortest duration of SPC, costs increased
between 62% and 79% (group A) and between 39% and
91% (group B) dependent on the duration of SPC – with
highest costs for 14–20 days SPC. Costs were higher in
the university hospital than in the non-university hospital.
MDC did not significantly influence costs.
Linear regression on costs per day showed that location
and the number of procedure codes significantly
Table 3 Mean costs and reimbursement per case in Euros, separated by cost categories and cost centers for group B (“palliative
care only” 2013; n = 784)
Physicians Nursing Medical/
technical staff
Drugs Implants/
grafts
Material bMedical
infrastructure
bNon-medical
infrastructure
Sum %
Cost matrix of palliative care cases
Ward 782 2465 35 87 0 100 464 1450 5382 93.4%
Intensive care 0 0 0 0 0 0 0 0 0 0.0%
Dialysis 0 0 0 0 0 0 0 0 0 0.0%
Operating room 3 0 4 0 3 3 2 2 17 0.3%
Anesthesia 3 0 2 0 0 1 0 1 7 0.1%
Cardiac diagnostics/
therapy
0 0 0 0 0 0 0 0 0 0.0%
Endoscopic diagnostics/
therapy
3 0 4 0 0 2 3 2 15 0.3%
Radiology 4 0 5 0 0 2 2 3 15 0.3%
Laboratory tests 1 0 6 8 0 11 1 2 29 0.5%
Further diagnostics/
therapy
27 0 148 4 0 12 36 71 298 5.2%
Sum 823 2465 204 100 4 130 507 1531 5763
% 14.3% 42.8% 3.5% 1.7% 0.1% 2.3% 8.8% 26.6%
Matrix used for reimbursementa
Ward 643 1295 12 158 0 63 340 1044 3615 84.5%
Intensive care 0 0 0 0 0 0 0 0 0 0.0%
Dialysis 0 0 0 0 0 0 0 0 0 0.0%
Operating room 3 0 2 0 6 1 1 2 18 0.4%
Anesthesia 2 0 1 0 0 0 0 1 5 0.1%
Cardiac diagnostics/
therapy
0 0 0 0 0 0 0 0 0 0.0%
Endoscopic diagnostics/
therapy
4 0 5 0 0 1 2 3 16 0.4%
Radiology 19 0 20 0 0 3 9 15 69 1.6%
Laboratory tests 18 0 77 4 0 34 11 36 212 5.0%
Further diagnostics/
therapy
90 0 142 3 0 8 20 72 343 8.0%
Sum 780 1295 259 166 6 111 383 1172 4278
% 18.3% 27.2% 8.7% 4.0% 0.4% 6.7% 8.8% 25.8%
aoverall absolute value represents actual reimbursement, distribution of absolute value represents hypothetical InEK calculation based on study patients
bmedical infrastructure: e.g. pharmacy, hygiene; non-medical infrastructure: e.g. management, energy, laundry
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fluenced costs per day for group A (see Additional file 2).
CART also identified total LOS as the most important
cost driver, followed by the kind of supplementary fee
for SPC which reflects duration of SPC (only for group
A). All other regression variables were no good classi-
fiers in CART (see Additional file 3).
Discussion
Cost and reimbursement situation
To our knowledge, this is the first study analysing costs
and reimbursement for individual SPC cases. Results show
that the current reimbursement system in Germany doesnot reflect the costs for SPC cases in the hospital. Given
the growing evidence that certain interventions or treat-
ments, e.g. laboratory tests or imaging, are less likely after
involvement of SPC, over-reimbursement for SPC in a
diagnosis-based reimbursement system would also have
been conceivable [24, 25]. On the contrary, both absolute
and relative differences between overall costs and overall
reimbursement in the study sample as well as between
costs and reimbursement of cost modules (ward vs. other
cost centers, and e.g. nurses versus other cost categories)
were large. This applies both for group A (all patients on
the PCU, including those treated on other hospital wards
before referral to the PCU) and for group B (patients
ab
Fig. 2 Benefit distribution of cases with highest benefit to highest loss (a) and with lowest to highest length of stay (b) for group A (n = 2151)
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externally referred, had a shorter LOS, lower costs and
smaller differences between costs and reimbursement.
The main reason for the smaller financing gap for group B
is probably the shorter LOS and the fact, that most costs
in PC are attributed to cases via LOS, whereas reimburse-
ment in the DRG system is not mainly influenced by LOS.
Thus, our data show that G-DRGs do not reproduce costs
for patients treated on the PCU, whether they had a phase
of “acute care” on a non-PC ward before referral to the
PCU or were treated on the PCU only. As costs or reim-
bursement for group A could not be differentiated by
“acute care phase” or PCU phase, it is not possible to draw
any conclusions regarding acute care alone.
Most of the financing gap between costs and reim-
bursement appeared for nursing costs on the cost centre
“ward”, while for laboratory tests, reimbursement was up
to 7-fold higher (group B) than the costs. Withinreimbursement calculation in the DRG-system, PC pa-
tients and non-PC cases are mixed up in a single DRG.
As ordinary cases are much more frequent, the more
complex and costly PC cases barely influence DRG reim-
bursement [4]. Within this costing system, the PCU is
thus treated like an ordinary ward, and use of resources
such as professionals’ time is poorly reflected. Nursing
and physician costs, however, are the biggest cost pool
for PC, and the ward makes up 84% of overall case costs
for group A and 93% for group B, while laboratory costs
play a marginal role. The situation is mitigated by sup-
plementary fees for the duration of SPC, otherwise the
discrepancy between costs and reimbursement would be
even higher.
Most studies on costs or cost-effectiveness in PC focus
on specific diseases, [26–28] few report on general in-
patient and outpatient PC costs [29–32]. Most work on
cost drivers and reimbursement is on the development
Fig. 3 Costs and length of stay per case for group A (n = 2151).
Notes: Bivariate relationship of length of stay (LOS) with costs. LOESS
fit line serves to smooth scatterplot data. R2 = 0.78
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DRG-system.[7, 9, 33]. Within the UK, a special reim-
bursement system for PC patients is currently evolving
[34]. This study shows that the German reimbursement
system needs changes, too, in order to meet the costs of
inpatient PC – for patients treated on non-PC wards
and then referred to the PCU as well as for those treated
on the PCU only. The current loss-making system may
disincentivise hospital palliative care. This is especially
problematic, as incentives for SPC at home are lacking,
too, and SPC at home is still not available all over the
country [35]. For an adequate, needs-oriented care for
PC patients, changes to the current reimbursement
system in order to achieve adequate reimbursement
are essential. In heavily ageing populations, the chal-
lenge to adapt the DRG system to more complex
needs in a multimorbid, multiply restricted patient
population may even extend beyond the scope of PC.Redefining DRGs for palliative care
One of our most important findings is that main diagno-
sis, by which current DRGs are mainly generated, is not
an adequate parameter to define costs for PC patients.
Significant cost drivers were the kind of supplementary
fee for SPC, which reflects the duration of SPC, and
total LOS. Both might only be sensitive cost drivers be-
cause the current costing system allocates most relevant
costs to cases dependent on their LOS. Cost drivers
identified in Australia like the complexity of the patient’s
situation - which is reflected in the time nurses and phy-
sicians spend for the patient – are not assessed in the
current system. Actual time spent is used increasingly as
a cost classifier in healthcare, and detailed costingsystems, so-called time-driven activity-based costing
(TDABC), exist to measure costs incurred [13, 36, 37].
There is an ongoing debate on G-DRG’s in PC. The
new hospice and palliative care law introduced in
Germany in 2015 allows hospitals to leave the DRG sys-
tem and negotiate day-related fees for PCUs with the
sickness funds. From 2017 onwards, individual supple-
mentary fees for SPC hospital advisory teams can be ne-
gotiated, which will be standardised for Germany in
2019. To adequately link reimbursement to the com-
plexity of the patients’ situation, we see a need to include
the variables used in Australia such as phase of illness,
functional status and problem severity [9, 33]. This
could be introduced on different levels: 1) Revising the
supplementary fee for SPC by inclusion of factors
reflecting complexity, 2) Introducing new “DRGs” for
PC patients, as already proposed by other authors, [4] sep-
arating cases based on complexity of the patients’ situation,
and 3) development of an entirely new reimbursement sys-
tem for PC outside the DRG system. Guided by the Austra-
lian and UK experiences, pilot studies are currently
underway to develop a casemix classification for German
PC, based on complexity of the patients’ situation. On the
cost side, elements of TDABC will be used in accordance
with the Australian study [9, 13, 36, 37].
Palliative care has been found to be cost-saving com-
pared to usual care, [24, 25, 31, 38–43] and the aging of
societies will considerably increase the need of palliative
care [44, 45]. An adequate financing system for inpatient
palliative care is thus key to a cost-conscious health care
system. Hospitals will benefit from adequate reimburse-
ment for PC patients that is calculated from actual PC
patients and not mainly from patients in similar
DRGs on normal wards. From a long-term policy per-
spective, this will turn PCUs from loss-making units
that have to be cross-subsidised to economically vi-
able units.
Strengths and limitations and a future perspective
A strength of this study is that we used actual reim-
bursement of our cases and distributed it on the matrix
according to the national calculation dataset, to make
cost and reimbursement calculation comparable. A limi-
tation is that we analysed only cases from two centres.
These may not be representative of all German PCUs. If
they were less efficient than other units, this could have
increased the financing gap [13]. In fact, costs were
higher in the university hospital than in the non-
university hospital, but this may well be explained by the
more complex conditions and needs of the patients
cared for. To reach a more representative case-mix for
PC in Germany, a multi-centre study is necessary. How-
ever, in the present study, a large number of cases was
analysed, and study patients were treated at a university
Table 4 GLM log link regression on costs per case
Group A = total group B = “palliative care only” group
Number of patients n = 2151 n = 784
Variable exp(b) (95% CI) p-value exp(b) (95% CI) p-value
Location BBM −36.3% (−39.2%; −33.3%) 0.000 −38,0% (−42,0%; − 33,8%) 0.000
LMU ref. ref.
Gender male −4.2% (−7.3%; −1.0%) 0.011 0,9% (−3,0%; 4,9%) 0.646
female ref. ref.
Kind of suppl. Fee for SPC SPC for 7–13 days 62.1% (55.7%; 68.8%) 0.000 39,4% (17,1%; 66,0%) 0.000
SPC for 14–20 days 79.3% (69.7%; 89.5%) 0.000 90,9% (66,7%; 118,5%) 0.000
SPC for ≥21 days 69.2% (55.3%; 84.5%) 0.000 60,9% (45,3%; 78,1%) 0.000
SPC for 0–6 days (=no fee) ref. ref.
Other suppl. Fee no −38.4% (−45.3%; − 30.8%) 0.000 −5,8% (−27,7%; 22,8%) 0.659
yes ref. ref.
Discharge home 6.8% (2.8%; 10.8%) 0.001 5,7% (1,0%; 10,7%) 0.018
to other hospital 3.6% (−9.0%; 17.8%) 0.595 30,7% (5,9%; 61,4%) 0.013
to hospice 7.5% (1.1%; 14.4%) 0.022 −0,3% (−7,7%; 7,6%) 0.935
to nursing home 8.5% (−1.6%; 19.7%) 0.101 6,3% (−4,4%; 18,2%) 0.259
other −5.7% (−20.0%; 11.2%) 0.485 −27,5% (− 41,0%; −10,8%) 0.002
death ref. ref.
MDC other 4.6% (−3.1%; 13.0%) 0.251 −0,2% (−8,6%; 9,0%) 0.973
nervous system 9.4% (1.3%; 18.1%) 0.022 7,9% (−1,1%; 17,7%) 0.086
respiratory system 2.6% (−4.8%; 10.5%) 0.499 4,6% (−3,8%; 13,9%) 0.292
digestive system −0.1% (−7.4%; 7.7%) 0.973 4,7% (−4,3%; 14,4%) 0.316
hepatobiliary system & pancreas 3.1% (−4.4%; 11.1%) 0.431 4,2% (−4,3%; 13,4%) 0.348
skin, subcutaneous tissue & breast −0.8% (−8.6%; 7.7%) 0.848 0,7% (−8,6%; 11,1%) 0.882
kidney and urinary tract 1.3% (−7.3%; 10.7%) 0.777 0,9% (−9,1%; 12,1%) 0.861
male reproductive system 4.4% (−4.9%; 14.7%) 0.367 −3,7% (−14,0%; 7,7%) 0.509
female reproductive system −0.4% (−9.1%; 9.1%) 0.924 4,2% (−6,3%; 15,8%) 0.452
poorly differentiated neoplasms ref. ref.
Age 0.1% (0.0%; 0.2%) 0.169 0,0% (−0,1%; 0,2%) 0.887
Length of stay 5.6% (5.3%; 6.0%) 0.000 11,3% (10,4%; 12,2%) 0.000
No. of side diagnoses 1.5% (1.1%; 1.8%) 0.000 1,1% (0,6%; 1,5%) 0.000
No. of procedure codes 0.0% (−0.4%; 0.5%) 0.982 1,8% (0,5%; 3,1%) 0.008
BBM (Hospital Barmherzige Brüder München), LMU (University Hospital Munich), MDC (main Diagnostic Category)
Bold numbers: significant results (α-level 0.05)
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German PC situation.
A further limitation is a time gap in the data used, as
InEK cost calculations refer to the preceding year. In
2012, a new procedure code was introduced in the G-
DRG system, reflecting the duration of SPC on PCUs.
The supplementary fee for this was introduced in 2014.
Therefore, the reimbursement data used here do not yet
entail this new supplementary fee, which may contribute
to a reduction of the financing gap in the future. Besides,
the G-DRG system is updated annually, which means
that every year slightly different base rates and DRGweights are applied. However, as we compare costs and
reimbursement on case level, this difference between
2012 and 2013 does not affect the total financing gap.
These aspects reflect a general challenge of evaluations
of international health care systems, which are continu-
ously changing. Evaluations are only possible with a time
lag due to the reasons mentioned above. If the system
has changed before the analysis is finished, the question
is open once again, whether the current reimbursement
system is reflecting the costs.
A general limitation of this study is that all reported
costs were calculated based on cost classifiers pre-
Vogl et al. BMC Palliative Care  (2018) 17:58 Page 10 of 11defined by the InEK costing scheme such as LOS, and
that the data do not include the variables identified as
significant cost drivers in Australia [9]. However, this
cost calculation method is the current national standard
in Germany, and thus provides a relevant starting point
for analysing the current situation. To better reflect the
costs accrued by the care for the individual patients, the
resources used by the patients, especially the time spent
with the patients by SPC team members, has to be re-
corded, i.e. a TDABC approach, as done in the Austra-
lian study, the ongoing UK study and planned in future
studies in Germany [9, 46].
Conclusions
Main diagnosis, by which current DRGs are mainly gen-
erated, is not an adequate parameter to define costs for
PC patients. Besides, G-DRGs do not reproduce costs
for inpatient PC episodes adequately. Possible reasons
for this are 1) the fact that PC patients differ from acute
patients on normal wards regarding the complexity of
their situation and the care they need, and 2) that the
cost classifiers currently used for DRG grouping poorly
reflect resource use – especially the use of professionals’
time, which accounts for the biggest cost pool in PC.
Studies collecting resource-use based cost data as well as
data on the cost drivers identified in Australia are
needed as a basis for further development of our costing
and reimbursement system for PC. Changes to the current
system are crucial to make PCUs economically viable and
enable them to provide adequate care to the increasing
number of patients in need of PC in the future.
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